Rankings
▼
Calendar
▼
NGEN FY 2017 Earnings Report — NervGen Pharma Corp. Common stock Revenue & Financial Results | Market Cap Arena
NervGen Pharma Corp. Common stock
NGEN
FY 2017 Earnings
Reported December 30, 2017
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
FY 2017
Prior Q
FY 2016
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$9.4K
—
—
—
—
EPS (Diluted)
$0.00
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$0
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$9.4K
Other Expenses
$0
Operating Expenses
$9.4K
Cost & Expenses
$9.4K
OPERATING INCOME
-$9.4K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$9.4K
Income Tax Expense
$0
Net Income from Continuing Ops
-$9.4K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$9.4K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$9.4K
D&A
$0
EBIT
-$9.4K
EBITDA
-$9.4K
EPS
$0
EPS Diluted
$0
marketcaparena.com
← Q4 2017
NGEN Overview